Article Menu

Export Article

More by Authors Links

Article Data

  • Views 3438
  • Dowloads 145

Original Research

Open Access

Docetaxel and nab-paclitaxel are safe alternative options for patients with gynecologic malignancies following hypersensitivity reaction to paclitaxel

  • R. Brightwell1,*,
  • E. Handel2
  • K. Eng3
  • K. Grzankowski1
  • P. Frederick1
  • K. Odunsi1
  • S. Lele1

1Department of Gynecologic Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA

2Department of Pharmacy, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA

3Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA

DOI: 10.12892/ejgo3308.2016 Vol.37,Issue 6,December 2016 pp.800-802

Published: 10 December 2016

*Corresponding Author(s): R. Brightwell E-mail: Rachel.Brightwell@Roswellpark.org

PDF (98.91 kB) View Full-text

Abstract

Docetaxel and nab-paclitaxel are safe alternatives to paclitaxel after hypersensitivity reaction occurs. There was no significant difference in overall survival between those that had paclitaxel, docetaxel, and nab-paclitaxel.

Keywords

Hypersensitivity; Reaction; Paclitaxel; Docetaxel; Nab-paclitaxel.

Cite and Share

R. Brightwell,E. Handel,K. Eng,K. Grzankowski,P. Frederick,K. Odunsi,S. Lele. Docetaxel and nab-paclitaxel are safe alternative options for patients with gynecologic malignancies following hypersensitivity reaction to paclitaxel. European Journal of Gynaecological Oncology. 2016. 37(6);800-802.

URL:

https://www.ejgo.net/articles/10.12892/ejgo3308.2016

References

[1] Gelderblom H., Verweij J., Nooter K., Sparreboom A.: “Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation”. Eur. J. Cancer, 2001, 37, 1590.

[2] Sanofi Aventis: “Taxotere (docetaxel) injection concentrate, intravenous infusion (IV). Highlights of prescribing information, 2014”. Available at: http://products.sanofi.us/Taxotere/taxotere.html#section-13

[3] Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al.: “Phase III randomized trial of docetaxel-carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma”. J. Natl. Cancer Inst., 2004, 96, 1682.

[4] Vasey P.A.: “Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer”. J. Clin. Oncol., 2001, 21, 136s.

[5] Chase D.M., Huang H., Foss C.D., Wenzel L.B., Monk B.J., Burger R.A.: “Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/ Gynecologic Oncology Group study”. Gynecol. Oncol., 2015, 136, 323.

[6] Cavaletti G., Bogliun G., Marzorati L., Zincone A., Piatti M., Colombo N., et al.: “Early predictors of peripheral neuropathy in cisplatin and paclitaxel combination chemotherapy”. Ann. Oncol., 2004, 15, 1439.

[7] Coleman R.L., Brady W.E., McMeekin D.S., Rose P.G., Soper J.T., Lentz S.S., et al.: “A phase II evaluation of nanoparticle, albuminbound (nab) paclitaxel in the treatment of recurrent or persistent platinum- resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study”. Gynecol. Oncol., 2011, 122, 111.

[8] Wang Y., Herrstedt J., Havsteen H., DePoint Christensen R., Mirza M.R., Lund B., et al.: “A multicenter, non-randomized phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer”. BMC Cancer, 2014, 14, 937.

Submission Turnaround Time

Top